Is canagliflozin better than dapagliflozin for treating type 2 diabetes?

Neither SGLT2 Inhibitor is Definitively "Better" - Selection Should Be Based on Specific Clinical Context

Both canagliflozin and dapagliflozin are effective SGLT2 inhibitors with proven cardiovascular and renal benefits, but they have distinct FDA-approved indications and safety profiles that should guide selection rather than assuming one is universally superior.

Key Differences in FDA-Approved Indications

Canagliflozin's Unique Advantages

• FDA-approved for reducing risk of MI, stroke, or CV death in adults with T2D and established CV disease 1
• FDA-approved for diabetic nephropathy with albuminuria - specifically indicated to reduce risk of end-stage kidney disease, doubling of serum creatinine, CV death, and hospitalization for heart failure 1
• Can be used down to eGFR 30 mL/min/1.73 m² (though max dose 100 mg daily for eGFR 30-59) 1

Dapagliflozin's Unique Advantages

• FDA-approved for heart failure with reduced ejection fraction (HFrEF) - regardless of diabetes status 1, 2
• FDA-approved for chronic kidney disease at risk of progression - broader CKD indication beyond just diabetic nephropathy 2
• Can be initiated down to eGFR 25 mL/min/1.73 m² and continued even if eGFR falls below 25 2
• No amputation risk signal - critical distinction from canagliflozin 3

Clinical Decision Algorithm

Choose Canagliflozin When:

• Primary goal is ASCVD risk reduction (MI/stroke prevention) in patients with established CV disease 1
• Patient has diabetic nephropathy with albuminuria (ACR ≥300 mg/g based on CREDENCE trial) 1, 4
• Patient has NO history of amputation, severe peripheral vascular disease, neuropathy, or diabetic foot ulcers 3
• Patient has NO history of osteoporosis or bone fracture risk 3

Choose Dapagliflozin When:

• Patient has heart failure (HFrEF or HFpEF) - this is dapagliflozin's strongest indication 1, 5, 2
• Patient has CKD at risk of progression (even without diabetes) 5, 4, 2
• Patient has eGFR 20-25 mL/min/1.73 m² where canagliflozin is not recommended 2
• Patient has amputation risk factors (prior amputation, severe PVD, neuropathy, foot ulcers) 3
• Patient has osteoporosis or fracture risk 3

Comparative Efficacy Data

Glycemic Control

Real-world evidence suggests canagliflozin 300 mg may provide slightly better HbA1c reduction than dapagliflozin 10 mg:

• One real-world study showed 70.8% vs 59.1% achieving HbA1c <8.0% (p=0.0001) 6
• Mean HbA1c reduction: -1.17% vs -0.91% (difference -0.26%, p=0.0049) 6
• Pharmacodynamic study showed canagliflozin had 25% higher 24-hour urinary glucose excretion 7

However, a 2025 meta-analysis of 280,617 patients found no significant difference in cardiovascular outcomes between empagliflozin and dapagliflozin 8, and a 2025 comparative effectiveness study found comparable MI/stroke risk between all three SGLT2 inhibitors at clinically effective doses 9.

Cardiovascular Outcomes

• MACE reduction: Both agents reduce MACE, but canagliflozin has specific FDA approval for MI/stroke reduction 1, 3
• Heart failure: Dapagliflozin has superior evidence and FDA approval for HF (DAPA-HF trial: 26% reduction in HF hospitalization/CV death, HR 0.74) 1
• Low-dose dapagliflozin (5 mg) showed reduced benefit for heart failure hospitalization (HR 1.30) compared to empagliflozin 9

Renal Outcomes

• Canagliflozin: CREDENCE trial demonstrated 44% reduction in composite renal outcome in diabetic nephropathy with albuminuria 4
• Dapagliflozin: DAPA-CKD trial showed 44% reduction in renal/CV composite in CKD with or without diabetes 5, 4
• Both can be continued as eGFR declines, but dapagliflozin can be initiated at lower eGFR (≥25 vs ≥30) 2

Critical Safety Distinctions

Canagliflozin-Specific Risks

• FDA Black Box Warning for lower-limb amputations - most frequently toe and midfoot 10, 3
• Increased bone fracture risk 3
• Use with extreme caution in patients with prior amputation, severe PVD, neuropathy, or active diabetic foot ulcers 1

Dapagliflozin Safety Profile

• No increased amputation risk observed to date 3
• Lower risk of diabetic ketoacidosis compared to empagliflozin (HR 0.78) 9
• Lower risk of genital infections compared to empagliflozin (HR 0.92) 9

Shared SGLT2i Risks (Both Agents)

• Genital mycotic infections (8-10% with dapagliflozin, 5-9% with canagliflozin) 11
• Euglycemic diabetic ketoacidosis - discontinue 3 days before surgery 1
• Volume depletion/hypotension - especially with diuretics or elderly 1
• Urinary tract infections 10

Practical Prescribing Considerations

Renal Function Thresholds

Canagliflozin 1:

• eGFR 30-59: Maximum 100 mg daily
• eGFR <30: Not recommended

Dapagliflozin 2:

• eGFR ≥25: Can initiate 10 mg daily
• eGFR <25: Can continue if already on therapy
• eGFR <45: Not recommended for glycemic control (but continue for CV/renal benefits)

Cost Considerations

• Both agents have similar costs (median AWP ~$620/month for maximum doses) 12
• Cost-effectiveness analyses favor canagliflozin for glycemic control due to better HbA1c reduction 13, 14
• However, clinical indication should drive selection, not cost alone

Common Pitfalls to Avoid

1. Don't use canagliflozin in patients with amputation risk factors - this is a critical safety distinction 3

2. Don't miss dapagliflozin's heart failure indication - it's the only SGLT2i with FDA approval for HFrEF regardless of diabetes status 1, 2

3. Don't stop SGLT2i when eGFR declines - continue therapy for CV/renal benefits even as glycemic efficacy wanes 4, 2, 15

4. Don't forget sick day protocols - hold SGLT2i during acute illness to prevent DKA and volume depletion 4, 2

5. Don't use low-dose dapagliflozin (5 mg) for heart failure - use 10 mg dose for CV/renal benefits 9

Bottom Line Recommendation

Select based on primary clinical indication:

• Heart failure dominant: Dapagliflozin (FDA-approved for HFrEF/HFpEF)
• ASCVD/stroke prevention: Canagliflozin (FDA-approved for MACE reduction)
• Diabetic nephropathy with albuminuria: Canagliflozin (CREDENCE trial data)
• CKD without diabetes: Dapagliflozin (broader CKD indication)
• Amputation/fracture risk: Dapagliflozin (no safety signals)
• Advanced CKD (eGFR 20-25): Dapagliflozin (can initiate at lower eGFR)

Both agents provide substantial cardiovascular and renal benefits 12, 5, 16, but the specific FDA-approved indications and safety profiles should guide selection rather than assuming one is universally superior.